Literature DB >> 12960028

Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness.

Frank Weekers1, Anna-Paula Giulietti, Marina Michalaki, Willy Coopmans, Erik Van Herck, Chantal Mathieu, Greet Van den Berghe.   

Abstract

Stress hyperglycemia is frequent in critically ill patients. The aim of this study was to investigate the effect of blood glucose control with insulin on endocrine, metabolic, and immune function in an animal model of severe injury. Seventy-two hours after alloxan injection and exogenous insulin infusion combined with continuous iv parenteral nutrition, male New Zealand White rabbits received a burn injury and were allocated to a normoglycemic (n = 17) or hyperglycemic (n = 13) group. In the normoglycemic group, blood glucose levels were kept between 3.3 and 6.1 mmol/liter by insulin infusion, whereas in the hyperglycemic group blood glucose levels were maintained at 13.8-16.6 mmol/liter. Blood was drawn for biochemical analysis at regular time points. At 24 and 72 h after burn injury, immune function of monocytes was assessed in vitro. Maintenance of normoglycemia with exogenous insulin after severe trauma to a large extent prevented weight loss, lactic acidosis, and hyponatremia. Furthermore, within 3 d after injury, the intervention improved phagocytosis of monocytes investigated in fresh cells by more than a mean 150% (P = 0.006) and after 24-h incubation with or without lipopolysaccharide by more than a mean 4-fold (P = 0.001) and 2-fold (P = 0.05), respectively. Oxidative killing after 24-h incubation was also improved by 2-fold (P = 0.05), but no effect on chemotaxis was detected. Concomitantly, inflammation and stress-induced growth hormone hypersecretion were suppressed. Prevention of catabolism, acidosis, excessive inflammation, and impaired innate immune function may explain previously documented beneficial effects of intensive insulin therapy on outcome of critical illness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960028     DOI: 10.1210/en.2003-0697

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  43 in total

Review 1.  Pituitary function during severe and life-threatening illnesses.

Authors:  C Gauna; G H van den Berghe; A J van der Lely
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Management of blood glucose in the critically ill in Australia and New Zealand: a practice survey and inception cohort study.

Authors:  Imogen Mitchell; Simon Finfer; Rinaldo Bellomo; Tracey Higlett
Journal:  Intensive Care Med       Date:  2006-04-19       Impact factor: 17.440

3.  Intensive versus conventional insulin therapy in type 2 diabetes patients undergoing D2 gastrectomy for gastric cancer: a randomized controlled trial.

Authors:  Shou-Gen Cao; Jian-An Ren; Bo Shen; Dong Chen; Yan-Bing Zhou; Jie-Shou Li
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

4.  Insulin therapy in the intensive care unit should be targeted to maintain blood glucose between 4.4 mmol/l and 6.1 mmol/l.

Authors:  G Van den Berghe
Journal:  Diabetologia       Date:  2007-11-27       Impact factor: 10.122

Review 5.  Intraoperative glycemic control procedures and the use of an artificial pancreas.

Authors:  Koichi Yamashita; Tomoaki Yatabe
Journal:  World J Gastroenterol       Date:  2009-09-07       Impact factor: 5.742

6.  Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged critically ill rabbits.

Authors:  Yves Debaveye; Björn Ellger; Liese Mebis; Theo J Visser; Veerle M Darras; Greet Van den Berghe
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 7.  New insights into insulin: The anti-inflammatory effect and its clinical relevance.

Authors:  Qiang Sun; Jia Li; Feng Gao
Journal:  World J Diabetes       Date:  2014-04-15

8.  Intensive insulin therapy protects the endothelium of critically ill patients.

Authors:  Lies Langouche; Ilse Vanhorebeek; Dirk Vlasselaers; Sarah Vander Perre; Pieter J Wouters; Kristin Skogstrand; Troels K Hansen; Greet Van den Berghe
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  Sex disparities in effects of cystic fibrosis-related diabetes on clinical outcomes: a matched study.

Authors:  R J Miller; H D Tildesley; P G Wilcox; H Zhang; S H Kreisman
Journal:  Can Respir J       Date:  2008-09       Impact factor: 2.409

10.  Organ failure and tight glycemic control in the SPRINT study.

Authors:  J Geoffrey Chase; Christopher G Pretty; Leesa Pfeifer; Geoffrey M Shaw; Jean-Charles Preiser; Aaron J Le Compte; Jessica Lin; Darren Hewett; Katherine T Moorhead; Thomas Desaive
Journal:  Crit Care       Date:  2010-08-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.